ALSO NOTED: Teva invests in stem cell start-up; Anacor files for IPO; Merrion sets terms; and much more...

> Teva is investing $1 million in the stem cell start-up Cell Cure Neurosciences. Report

> Anacor Pharmaceuticals has filed documents for an IPO designed to raise $57.5 million. Report

> Ireland's Merrion Pharmaceuticals says it plans to offer four million shares in its IPO at $10 to $12 per share. Report

> Celera is buying Berkeley HeartLab for $195 million in cash. "Celera's genetic markers that are intended to identify people at risk for early heart attacks, stroke and blood clots and optimize therapy with cholesterol-lowering drugs, aspirin, anti-coagulants and other cardiovascular drugs should augment Berkeley HeartLab's current disease management offerings to patients," said Kathy Ordonez, president of Celera. Report

> The FDA has approved a new vaccine--ACAM2000--for use against smallpox. Release

> Jerini announced the termination of the license agreement between its affiliate, Jerini US, and Kos Life Sciences, Inc. for the development, marketing, and distribution of Icatibant in the United States and Canada. Release

> More proof that India is the new headwaters of generic drug-making: Watson Pharmaceuticals got the FDA to sign off on its production facility in Goa, India. Report

And Finally… Craig Ventner's new work sequencing his own diploid genome has created a new "gold standard" in the field of genetics. FierceBioResearcher

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.